{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:58:31Z","timestamp":1788872311458,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["WE 4388\/3-1"],"award-info":[{"award-number":["WE 4388\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["WE 4388\/6-1"],"award-info":[{"award-number":["WE 4388\/6-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Discovery Today: Technologies"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ddtec.2013.12.003","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T22:15:25Z","timestamp":1389305725000},"page":"19-25","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development"],"prefix":"10.1016","volume":"11","author":[{"given":"Christoph","family":"Welsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ddtec.2013.12.003_bib0005","first-page":"35","article-title":"Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board","volume":"6","author":"Global Surveillance and Control of Hepatitis C","year":"1999","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0010","doi-asserted-by":"crossref","first-page":"i36","DOI":"10.1136\/gutjnl-2012-302144","article-title":"New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives","volume":"61","author":"Welsch","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.ddtec.2013.12.003_bib0015","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1053\/j.gastro.2011.12.062","article-title":"Will interferon-free regimens prevail?","volume":"142","author":"Welsch","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ddtec.2013.12.003_bib0020","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.coviro.2012.08.008","article-title":"Clinical relevance of HCV antiviral drug resistance","volume":"2","author":"Welsch","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/(SICI)1099-1654(199707)7:2<87::AID-RMV188>3.0.CO;2-0","article-title":"RNA virus fitness","volume":"7","author":"Domingo","year":"1997","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0030","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/35020564","article-title":"Evolvability of an RNA virus is determined by its mutational neighbourhood","volume":"406","author":"Burch","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ddtec.2013.12.003_bib0035","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"Rong","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ddtec.2013.12.003_bib0045","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0050","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0055","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ddtec.2013.12.003_sbref0060","doi-asserted-by":"crossref","first-page":"20509","DOI":"10.1073\/pnas.1105797108","article-title":"Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance","volume":"108","author":"Powdrill","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0065","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(11)70314-0","article-title":"Selection of chronic hepatitis B therapy with high barrier to resistance","volume":"12","author":"Gish","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0070","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0075","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ddtec.2013.12.003_bib0080","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bpg.2012.09.011","article-title":"The role of resistance in HCV treatment","volume":"26","author":"Vermehren","year":"2012","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0085","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ddtec.2013.12.003_bib0090","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0095","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1128\/MMBR.05023-11","article-title":"Viral quasispecies evolution","volume":"76","author":"Domingo","year":"2012","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.ddtec.2013.12.003_sbref0100","doi-asserted-by":"crossref","first-page":"20166","DOI":"10.1073\/pnas.1110064108","article-title":"Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID","volume":"108","author":"Jabara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ddtec.2013.12.003_sbref0105","doi-asserted-by":"crossref","first-page":"14508","DOI":"10.1073\/pnas.1208715109","article-title":"Detection of ultra-rare mutations by next-generation sequencing","volume":"109","author":"Schmitt","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ddtec.2013.12.003_sbref0110","doi-asserted-by":"crossref","first-page":"9530","DOI":"10.1073\/pnas.1105422108","article-title":"Detection and quantification of rare mutations with massively parallel sequencing","volume":"108","author":"Kinde","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ddtec.2013.12.003_sbref0115","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2010.10.056","article-title":"Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus","volume":"140","author":"Shimakami","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ddtec.2013.12.003_bib0120","doi-asserted-by":"crossref","first-page":"22741","DOI":"10.1074\/jbc.R109.099556","article-title":"Induction and evasion of innate antiviral responses by hepatitis C virus","volume":"285","author":"Lemon","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0125","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1128\/AAC.05184-11","article-title":"Ketoamide resistance and hepatitis C virus fitness in Val55 variants of the NS3 protease","volume":"56","author":"Welsch","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0130","doi-asserted-by":"crossref","first-page":"e1001233","DOI":"10.1371\/journal.ppat.1001233","article-title":"Structural and functional studies of nonstructural protein 2 of the hepatitis C virus reveal its key role as organizer of virion assembly","volume":"6","author":"Jirasko","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0135","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/JVI.01070-10","article-title":"Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins","volume":"85","author":"Ma","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0140","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1128\/JVI.00724-08","article-title":"NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly","volume":"82","author":"Ma","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0145","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0969-2126(00)80025-8","article-title":"Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease\u2013helicase","volume":"7","author":"Yao","year":"1999","journal-title":"Structure"},{"key":"10.1016\/j.ddtec.2013.12.003_bib0150","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1110\/ps.8.6.1332","article-title":"A novel recombinant single-chain hepatitis C virus NS3\u2013NS4A protein with improved helicase activity","volume":"8","author":"Howe","year":"1999","journal-title":"Protein Sci."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0155","doi-asserted-by":"crossref","first-page":"34913","DOI":"10.1074\/jbc.M707165200","article-title":"The serine protease domain of hepatitis C viral NS3 activates RNA helicase activity by promoting the binding of RNA substrate","volume":"282","author":"Beran","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0160","doi-asserted-by":"crossref","first-page":"29929","DOI":"10.1074\/jbc.M804065200","article-title":"Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase","volume":"283","author":"Beran","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ddtec.2013.12.003_sbref0165","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nchembio.1081","article-title":"Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function","volume":"8","author":"Saalau-Bethell","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0170","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1128\/AAC.00444-08","article-title":"Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479","volume":"52","author":"Ali","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0175","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00433-06","article-title":"General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2\u2032-modified nucleotide analogues","volume":"50","author":"Dutartre","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0180","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1128\/JVI.01890-06","article-title":"Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus","volume":"81","author":"Yi","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0185","doi-asserted-by":"crossref","first-page":"S490","DOI":"10.1016\/S0168-8278(11)61242-7","article-title":"Analysis of complex mutation patterns in the HCV quasispecies of patients treated with telaprevir or boceprevir","volume":"54","author":"Susser","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0190","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1128\/AAC.02494-12","article-title":"Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir","volume":"57","author":"Wang","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ddtec.2013.12.003_sbref0195","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1053\/j.gastro.2011.11.035","article-title":"Peptidomimetic escape arise due to genetic diversity in the ligand-binding site of the HCV NS3\/4A serine protease","volume":"142","author":"Welsch","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ddtec.2013.12.003_bib0200","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcv.2011.08.015","article-title":"Analysis of long-term persistance of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir","volume":"52","author":"Susser","year":"2011","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.ddtec.2013.12.003_bib0205","first-page":"485A-6A","article-title":"Follow-up of SVR durability and viral resistance in patients with chronic hepatitis C treated with telaprevir-based regimens: interim analysis of the extend study","volume":"54","author":"Sherman","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ddtec.2013.12.003_bib0210","first-page":"440A","article-title":"Analysis of resistance-associated amino acid variants (RAVS) in non-SVR patients enrolled in a retrospective long-term follow-up analysis of boceprevir phase 3 clinical studies","volume":"54","author":"Barnard","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ddtec.2013.12.003_bib0215","series-title":"7th InternationalWorkshop on Hepatitis C \u2013 Resistance & New Compounds","author":"McPhee","year":"2012"},{"key":"10.1016\/j.ddtec.2013.12.003_bib0220","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/jac\/dkt019","article-title":"Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus","volume":"68","author":"Bagaglio","year":"2013","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Drug Discovery Today: Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1740674913000589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1740674913000589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T03:27:22Z","timestamp":1565062042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1740674913000589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":44,"alternative-id":["S1740674913000589"],"URL":"https:\/\/doi.org\/10.1016\/j.ddtec.2013.12.003","relation":{},"ISSN":["1740-6749"],"issn-type":[{"value":"1740-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}